To disseminate information and provide leadership related to health economics and outcomes research of precision medicine and advanced therapies.
- Establish a forum for members to engage in discussion related to the challenges of translating precision medicine and advanced therapies into clinical practice.
- Promote education related to the health economics of precision medicine and advanced therapies.
- Investigate the demonstration of value and the use of innovative payment models for precision medicine, cell therapies, gene therapies, and tissue-engineered products
The term "precision medicine" is often described as providing "the right patient with the right drug at the right dose at the right time.” More broadly, precision medicine (also known as personalized medicine) may be thought of as the tailoring of a medical treatment to the individual’s characteristics, needs, and preferences during all stages of care, including prevention, diagnosis, treatment, and follow-up. Advance therapies (also known as regenerative medicine), which include cell therapies, gene therapies, and tissue-engineered products are used in the precision medicine approach to care. These advanced therapies are often one-time treatments that are potentially curative. Together, precision medicine and advanced therapies reflect some of the most cutting-edge medical technologies available, but these therapies have unique considerations and are very different than traditional medications. The Precision Medicine and Advanced Therapies Special Interest Group seeks to explore issues related to the approval, payment, utilization, and evidence development related to the use of these technologies so they can be better used to improve the population’s health.
Manuscripts and Reports
- Zimmermann, B, Spinner, D. S, Snyder, S.R, Purser, M. Can We Demonstrate the Value of Next-Generation Sequencing Approaches Within Traditional Value Frameworks? Value and Outcomes Spotlight. 2021; 7(5)
- Faulkner, E, Holtorf, A-P, Walton, S, et al. Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group. Value in Health. 2020; 23(5):529 – 539
- Faulkner E, Annemans L, Garrison L, et al. Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health. 2012;15(8):1162-1171
- Virtual ISPOR Europe 2020: Can We Demonstrate The Value Of Next-Generation Diagnostic Testing Approaches Within Traditional Value Frameworks?
- ISPOR Europe 2019: ISPOR personalized precision medicine special interest group- translating genomic technologies into clinical practice – are we falling short? – What are the challenges? Over-coming the challenges? – Are we inadvertently creating disparities
- ISPOR 2019: ISPOR personalized precision medicine special interest group- leveraging real world evidence to address uncertainty for transformative and curative therapies
Ka Keat Lim, MSc, RPh, PhD
Renske ten Ham, PharmD
Melanie Whittington, MS, PhD
These activities allow for a variety of members to participate and also facilitates disseminating content.